

Gait Analysis for the Quantification of Neuropathic Foot Pain: A Step in the Right Direction

1. Department of Perioperative Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 2. Pain Research Center, National Institutes of Health, Bethesda, MD, USA

Abstract

Evaluation of pain often relies on subjective patient reported outcomes (PROs) such as the Numerical Rating Scale. Supplementing such measures with objective endpoints can provide a deeper assessment of acute and chronic pain. In the present study, we evaluate quantitative gait analysis using a podiatric walkway that records pressure measurements and spatiotemporal parameters during a full gait cycle. We recruited healthy volunteers and patients with symptomatic Morton neuroma pain (MN). Consented participants completed questionnaires assessing pain, physical functioning, and quality of life. We hypothesized that patients with MN pain would have abnormal gait and altered pressure loading from the affected foot detectable using gait analysis. Data show significant differences in measurements taken from the affected feet of MN patients, supporting gait analysis as an informative adjunct to subjective pain assessments and a potentially useful tool in measuring response to novel interventional treatments. This work will inform future studies that seek to initiate treatment with the non-opioid interventional analgesic resiniferatoxin (RTX) for MN pain and other painful neuropathic conditions.

Recruitment of study participants





Figure 2. Patient Reported Outcomes. Questionnaires were used to confirm the absence of painful conditions in healthy volunteers and quantify pain severity and disability in pain patients.

Sadé Orejobi,¹ Matthew R. Sapio,¹ Miroslav Bačkonja,² Michael J. ladarola¹, Andrew J Mannes¹

Gait analysis for functional outcomes in interventional pain management



Figure 3. Pressure heat mapping of 2 **MN** patients with Lsided lesions. Affected feet show a smaller area of maximal plantar pressure (red) compared to nonaffected feet.

We expect to find lower maximal pressure under the metatarsals of patients with symptomatic MN pain.

- Composite frames show the highest pressure experienced by each part of the foot during all foot strikes.
- Pressure data were collected from software-templated regions; Metatarsal was chosen for analysis.

Excluded (N = 17 HV; N = 1 MN)

- Pain not due to Morton Neuroma (N = 12 HV)
- Non-painful condition affecting gait (N = 5 HV)
- Resolution of pain (N = 1 MN)

Lost to follow-up

(N = 12 HV; N = 2 MN)

Figure 4C. Pooled averages for metatarsal peak pressure of Pain and No Pain feet in MN patients, at different speeds. We observed significantly lower MPP in the affected feet of MN (588+40.23 kPa) compared to non-affected MN feet (642.16+30.17 kPa); p=0.02.

Figure 4D. Pairing of Pain and No Pain sides. MN patients demonstrate variability of gait patterns, which may reflect individual differences in compensatory mechanisms.

Patient demographics

	Healthy (N=42)	Morton Neuroma (N=10)	Total (N=52)
Median age — yr (range)	32 (20-73)	57 (35-72)	40 (20-73)
Age group — no. (%)			
20-39	24 (57.1)	1 (10)	25 (48.1)
40-59	14 (33.3)	4 (40)	18 (34.6)
60+	4 (9.5)	5 (50)	9 (17.3)
Sex — no. (%)			
Female sex	26 (61.9)	8 (80)	34 (65.4)
Male sex	16 (38.1)	2 (20)	18 (34.6)
Race or ethnic group — no. (%)			
Asian	8 (19)	0	8 (15.4)
Black	11 (26.2)	0	11 (21.1)
White	20 (47.6)	10 (100)	30 (57.7)
2+ races, Other	3 (7.1)	0	3 (5.8)
Hispanic or Latino (of any race)	3 (7.1)	0	3 (5.8)
BMI class — no. (%)			
<18.5	2 (4.8)	0	2 (3.8)
18.5-24.9	17 (40.5)	4 (40)	21 (40.4)
25-29.9	15 (35.7)	3 (30)	18 (34.6)
30-34.9	5 (11.9)	3 (30)	8 (15.4)
>35	3 (7.1)	0	3 (5.8)





Figure 4A. Comparison of metatarsal peak pressure between all HV feet and symptomatic MN feet. Significant betweengroup differences in MPP were not detected at any speed. 4B. Comparison of distance variables between all HV feet and symptomatic MN feet. MN patients demonstrated reduced step length (p=0.01) and stride length (p=0.03).



Metatarsal Peak Pressure

Conclusions & Future Directions

- pressure measurements.
- in MN.
- gait measurements for both feet of individual MN patients.
- post-perineural RTX injection in MN patients.

Research support was provided by the NIH Medical Research Scholars Program, a public-private partnership supported jointly by the NIH and contributions to the Foundation for the NIH from private donors.



Collected data demonstrate stability of spatiotemporal parameters and plantar

We detected significant differences in spatiotemporal parameters of gait between HV and MN, and asymmetry of pressure loading between affected and non-affected feet

Results of metatarsal pressure measurements in MN may reflect individual differences in compensatory gait changes developed from chronic pain.

Future analyses will correlate PROs of pain and functional limitation with observed

Future studies will use gait analysis to supplement functional outcomes in pre- and